EUCTR2006-003108-20-IT进行中（未招募）不适用
A DOUBLE BLIND, RANDOMISED, PARALLEL, PLACEBO-CONTROLLED, PILOT STUDY TO EVALUATE THE ANTI-INFLAMMATORY EFFECTS AND THE EFFICACY OF RUPATADINE 10 MG ON THE SYMPTOMS OF PERSISTENT ALLERGIC RHINITIS - ND
RIACH J. URIACH Y COMPANIA S.A.0 个研究点目标入组 30 人开始时间: 2007年1月15日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •PATIENT AGREEING TO PARTICIPATE BY SIGNING THE INFORMED CONSENT FORM MALE OR FEMALE AGE OR EQUAL 18 AND OR EQUAL 65 PATIENTS WITH A CLINICAL HISTORY OF PERSISTENT ALLERGIC RHINOCONJUNCTIVITIS ACCORDING TO ARIA GUIDELINES 12 FROM AT LEAST 1 YEAR POSITIVE SKIN PRICK TEST OR RAST AT LEAST CLASS II FOR PARIETARIA JUDAICA LABORATORY BIOCHEMICAL AND HEMATOLOGY RESULTS WITHIN NORMAL RANGES. IF THE PATIENT HAS A RESULT OUTSIDE OF THESE RANGES, IN ORDER TO BE INCLUDED, THE RESEARCHER SHOULD CONSIDER IT NOT CLINICALLY SIGNIFICANT.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •PREGNANCY, BREAST FEEDING, OR OF CHILDBEARING POTENTIAL FEMALES WHO ARE NOT USING A MEDICALLY ACCEPTED CONTRACEPTIVE METHOD CLINICALLY SIGNIFICANT SENSITISATION TO ALLERGENS OTHER THAN PARIETARIA JUDAICA CAT AND DOG ALLOWED IF PATIENTS HAVE NO PETS AT HOME , KNOWN HYPERSENSITIVITY TO THE STUDY DRUG OR TO COMPOUNDS WITH A SIMILAR STRUCTURE OR TO ANY OF ITS COMPONENTS, SUCH AS LACTOSE-INTOLERANT PATIENTS. ASTHMATICS PATIENTS DISEASES REQUIRING TREATMENT WITH CORTICOSTEROIDS ASSOCIATED ENT DISEASES VASOMOTOR RHINITIS, NASAL POLYPOSIS, SEVERE DEVIATION OF NASAL SEPTUM, SINUSITIS COEXISTENCE OF OTHER CLINICALLY SIGNIFICANT DISEASE PATIENTS TAKING MEDICATION THAT INTERACTS WITH ISOENZYME CYP3A4 OF CYTOCHROME P45O AS IS THE CASE OF AMIODARONE, CARBAMAZEPINE, CYCLOSPORINE, TERFENADINE, GLUCOCORTICOIDS, PHENYTOIN, RIFAMPICIN, ERYTHROMYCIN AND KETOCONAZOLE AS WELL AS GRAPEFRUIT JUICE. PATIENTS CONSIDERED NON-RESPONSIVE TO ANTIHISTAMINE TREATMENT BY THE RESEARCHER, AFTER REVIEWING THE CASE HISTORY. PATIENTS WITH PSYCHIATRIC, VASCULAR, HEPATIC, RENAL, NEUROLOGIC, ENDOCRINE OR OTHER SYSTEMIC DISEASE AS WELL AS PATIENTS WHO, IN THE RESEARCHERS JUDGMENT, ENCUMBER THE APPLICATION OF THE PROTOCOL OR THE INTERPRETATION OF THE RESULTS OF THE STUDY. PATIENTS WHO MANIPULATE HEAVY MACHINERY OR DRIVE VEHICLES AS A FUNDAMENTAL PART OF THEIR JOB. PATIENTS WHO TAKE DRUGS STRONGLY ASSOCIATED WITH TORSADE DE POINTES SUCH AS DISOPYRAMIDE, PROCAINAMIDE, QUINIDINE, AMIODARONE, SOTALOL, THIORIDAZINE, BEPRIDIL OR PRENYLAMINE. PARTICIPATION TO CLINICAL TRIALS IN THE LAST 3 MONTHS PATIENTS CURRENTLY OR FORMERLY ABUSING ALCOHOL OR ILLICIT DRUGS PATIENTS OVER OR UNDER 40 NORMAL WEIGHT ACCORDING TO STANDARD BMI. PATIENTS WHO UNDERWENT NASAL SURGERY IN THE PAST 6 MONTHS PATIENTS WHO RECEIVED SPECIFIC IMMUNOTHERAPY LAST INTAKE AT LEAST 5 YEARS SINCE V1
研究者
相似试验
未知
不适用
A STUDY ASSESSING THE EFFICACY AND SAFETY OF SARILUMAB ADDED TO NON-BIOLOGIC DMARD THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS.-M069M069PER-033-13Sanofi Aventis Recherche & Development,67
进行中（未招募）
1 期
Wharton´s jelly derived mesenchymal stromal cell treatment of adult patients diagnosed with type I diabetes.MedDRA version: 20.0 Level: LLT Classification code 10012594 Term: Diabetes System Organ Class: 100000004861Type 1 diabetesEUCTR2017-002766-50-SEextCell Pharma24
进行中（未招募）
不适用
A TWO-PART, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER STUDY TO INVESTIGATE THE USE OF MEPOLIZUMAB (SB-240563) IN REDUCING THE NEED FOR SURGERY IN SUBJECTS WITH SEVERE BILATERAL NASAL POLYPOSISEUCTR2008-003772-21-NLGlaxoSmithKline Research & Development Limited110
进行中（未招募）
1 期
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, MULTICENTRE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ORAL GW677954 CAPSULES 2.5mg, 5mg, 10mg AND 20mg A DAY FOR WEEKS IN OVERWEIGHT DYSLIPIDAEMIC SUBJECTSDyslipidaemia and overweightMedDRA version: 7.1Level: LLTClassification code 10052066EUCTR2005-001558-26-ESGlaxoSmithKline, S.A.
进行中（未招募）
1 期
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, MULTICENTRE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ORAL GW677954 CAPSULES 2.5mg, 5mg, 10mg AND 20mg A DAY FOR WEEKS IN OVERWEIGHT DYSLIPIDAEMIC SUBJECTSOverweight Dyslipidaemic SubjectsMedDRA version: 7.1Level: LLTClassification code 10052066EUCTR2005-001558-26-SKGlaxoSmithKline290